Garda Therapeutics Set to Launch $125M Tender Offer for Assertio — Assertio Holdings, Inc.

Event summary

Garda Therapeutics to commence tender offer for Assertio on April 29, 2026, following a 20-day 'window-shop' period
Assertio shareholders to receive $18.00 per share in cash plus contingent value rights
Total deal valued at $125.1 million
Reduced breakup fee applies if Assertio terminates agreement for superior bid

The big picture

This acquisition reflects ongoing consolidation in the pharmaceutical sector as companies seek to strengthen their portfolios. The $125.1 million deal highlights Garda's strategic move to expand its commercial capabilities, particularly in oncology. The inclusion of a contingent value right suggests potential future milestones tied to product performance or market conditions.

What we're watching

Competing Bids: Whether other parties will emerge with superior offers during the tender process, potentially altering the transaction dynamics.
Regulatory Approval: The pace at which regulatory approvals are obtained and any potential hurdles that could delay or derail the acquisition.
Shareholder Response: How Assertio shareholders will respond to the tender offer, particularly regarding the acceptance rate and potential for holdout shares.